

Amexdrug Corporation

(Exact name of registrant as specified in its charter)

NEVADA 90-0017017 (State
or other jurisdiction of (I.R.S. Employer identification No.) incorporation
or organization)

7251 Condor Street
Commerce, California 90040
(Address of principal executive offices) (Zip code)

Registrant's telephone number: (323) 725-3100

IR Contact

Jack Amin
7251 Condor Street
Commerce, CA 90040
(323) 725-3100

Trading Symbol: AXRX
CUSIP: 031139207 Par
Value: \$0.001
Total shares authorized: 1,000,000,000 as of June 30, 2017 Total shares
outstanding: 169,409,620 as of June 30, 2017

Transfer Agent

Fidelity Transfer
8915 South 700 East
Salt Lake City, UT 84070
Tel: 801-562-1300
The Transfer Agent is registered under the Exchange Act.

Issuance History

In the past two years, the Company has not conducted any private placements of equity securities or convertible debt financing.

TABLE OF CONTENTS

	<u>Page</u>
Item 3. Condensed Financial Statements (Unaudited).....	3
Condensed Consolidated Balance Sheets — As of June 30, 2017 and December 31, 2016.....	4
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2017 and 2016.....	5
Condensed Statements of Shareholders Equity for the Six Months Ended June 30, 2017.....	6
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016.....	7
Notes to Condensed Consolidated Financial Statements (Unaudited).....	8-10
Item 4. Business Segment Information.....	11-12
Item 5. Identification of Directors and Executive Officers.....	13
Item 6. Legal Proceedings.....	13
Item 7. Certifications.....	14

Item 3. Financial Statements.

The condensed consolidated balance sheets of Amexdrug Corporation, a Nevada corporation, and subsidiaries as of June 30, 2017 and December 31, 2016, the related condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016, the related condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016, and the notes to the condensed consolidated financial statements. The condensed consolidated financial statements have been prepared by Amexdrug's management.

The accompanying consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to present fairly the results of operations and financial position of Amexdrug Corporation consolidated with BioRx Pharmaceuticals, Inc., Allied Med, Inc., and Dermagen, Inc., its wholly owned subsidiaries, and all such adjustments are of a normal recurring nature. The names "Amexdrug", "we", "our" and "us" used in this report refer to Amexdrug Corporation.

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	June 30, 2017	December 31, 2016
Assets		
Current Assets		
Cash and cash equivalents	\$ 94,004	\$ 218,574
Investment	8,756	3,604
Accounts receivable	799,348	849,566
Inventory	1,451,635	1,019,821
Other asset	110,674	157,465
Deferred tax asset	13,600	13,600
Total Current Assets	2,478,017	2,262,630
Property and Equipment, at net	12,180	15,892
Other Assets		
Other deposits	30,362	30,362
Goodwill	17,765	17,765
Total Other Assets	48,127	48,127
Total Assets	\$ 2,538,324	\$ 2,326,649
Liabilities and Shareholders' Equity		
Current Liabilities:		
Accounts payable and accrued expenses	\$ 631,853	\$ 780,649
Corporate tax payable	40,377	40,377
Notes payable related parties	108,023	108,023
Line of credit	460,000	700,000
Total Current Liabilities	1,240,253	1,629,049
Shareholders' Equity		
Common stock, \$0.0001 par value; 1,000,000,000 authorized common shares 169,409,620 shares issued and outstanding, respectively	169,410	169,410
Additional paid in capital	(77,594)	(77,594)
Treasury stock	(23,799)	(21,947)
Retained earnings	1,230,054	627,731
Total Shareholders' Equity	1,298,071	697,600
Total Liabilities and Shareholders' Equity	\$ 2,538,324	\$ 2,326,649

The accompanying notes are an integral part of these condensed consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2017	June 30, 2016	June 30, 2017	June 30, 2016
Sales	\$ 2,971,211	\$ 2,155,528	\$ 5,624,524	\$ 4,498,211
Cost of Goods Sold	1,914,872	1,777,983	3,976,590	3,552,449
Gross Profit	1,056,339	377,545	1,647,934	945,762
Operating Expenses				
Selling, general and administrative expense	568,698	217,825	980,491	428,220
Total Operating Expenses	568,698	217,825	980,491	428,220
Income before depreciation expense	487,641	159,720	667,443	517,542
Depreciation and amortization expense	1,936	1,977	3,711	3,794
Income before Other Income/(Expenses)	485,705	157,743	663,732	513,748
Other Income/(Expenses)				
Interest and other income	22	-	67	-
Penalty	-	-	-	-
Write off of obsolete inventory	-	-	-	-
Unrealized gain/(loss)	1,019	-	3,383	-
Interest expense	(12,651)	(8,498)	(23,859)	(17,459)
Total Other Income/(Expenses)	(11,610)	(8,498)	(20,409)	(17,459)
Income before Provision for Income Taxes	474,095	149,245	643,323	496,289
Income tax (expense) benefit	(27,000)	(164)	(41,000)	(133,744)
Net Income	<u>\$ 447,095</u>	<u>\$ 149,081</u>	<u>\$ 602,323</u>	<u>\$ 362,545</u>
BASIC AND DILUTED INCOME PER SHARE	<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 0.00</u>
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING				
BASIC AND DILUTED	<u>169,409,620</u>	<u>169,409,620</u>	<u>169,409,620</u>	<u>169,409,620</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY
FOR THE SIX MONTHS ENDED JUNE 30, 2017
(Unaudited)

	Common stock		Additional Paid-in Capital Deficit	Treasury Stock	Retained Earnings	Total Shareholders' Equity
	Shares	Amount				
Balance at December 31, 2016	169,409,620	\$ 169,410	\$ (77,594)	\$ (21,947)	\$ 627,731	\$ 697,600
Treasury stock	-	-	-	(1,852)	-	(1,852)
Net income for the six months ended June 30, 2017	-	-	-	-	602,323	602,323
Balance at June 30, 2017 (unaudited)	169,409,620	\$ 169,410	\$ (77,594)	\$ (23,799)	\$ 1,230,054	\$ 1,298,071

The accompanying notes are an integral part of these condensed consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND 2016
(Unaudited)

	Six Months Ended	
	June 30, 2017	June 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 602,323	362,545
Adjustment to reconcile net income to net cash used in operating activities		
Depreciation and amortization	3,711	3,794
Unrealized (gain)/loss on investment	(5,151)	-
Change in Assets and Liabilities		
(Increase) Decrease in:		
Accounts receivable	50,218	(114,263)
Inventory	(431,814)	2,166
Prepaid expenses	-	160,224
Deferred tax asset	-	(1,500)
Other assets	46,791	(222,197)
Increase (Decrease) in:		
Accounts payable and accrued liabilities	(148,796)	(25,604)
Corporate income tax payable	-	123,427
NET CASH PROVIDED IN OPERATING ACTIVITIES	117,282	288,592
CASH FLOWS FROM INVESTING ACTIVITIES:	-	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Purchase of treasury stock	(1,852)	-
Proceeds from credit line	-	875,000
Payments on credit line	(240,000)	(1,205,000)
NET CASH USED BY FINANCING ACTIVITIES	(241,852)	(330,000)
NET DECREASE IN CASH	(124,570)	(41,408)
CASH, BEGINNING OF PERIOD	218,574	235,703
CASH, END OF PERIOD	\$ 94,004	\$ 194,295
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION		
Interest paid	\$ 11,208	\$ 17,459
Income taxes	\$ 41,000	\$ -

The accompanying notes are an integral part of these condensed consolidated financial statements

AMEXDRUG CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (UNAUDITED)
JUNE 30, 2017

1. Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information refer to the financial statements and footnotes thereto included in the Company's annual filing for the year ended December 31, 2016.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of Amexdrug Corporation is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Revenue Recognition

The Company generates revenues from the manufacture and resale of pharmaceuticals, over-the-counter products, health and beauty care products and nutritional supplements. The Company accounts for these revenues at the time of shipment to the customer. An allowance for sales returns is provided for products sold on a cash-on-delivery basis that are not accepted or paid for by the customer.

Cash and Cash Equivalent

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Investments

Certificate of Deposits with banking institutions are short-term investments with initial maturities of more than 90 days. The carrying amount of these investments is a reasonable estimate of fair value due to their short-term nature.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, and the fair value of stock options. Actual results could differ from those estimates.

Property and Equipment

Property and equipment are stated at cost, and are depreciated using the modified accelerated cost recovery system (macrs) method over its estimated useful lives:

Machinery & Office equipment	3-10 Years
Leasehold improvements	2-5 Years

Depreciation expense was \$3,711 and \$3,794 for the six months ended June 30, 2017 and 2016, respectively.

AMEXDRUG CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIALS – (UNAUDITED)
JUNE 30, 2017

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2017, the amounts reported for cash, accounts receivable, accounts payable, accrued interest and other expenses, and notes payable approximate the fair value because of their short maturities.

Basic Income per Share Calculations

Basic income per share is computed by dividing net income by the weighted-average number of common shares outstanding. As of June 30, 2017 and 2016, the Company did not have any potentially issuable common shares outstanding; accordingly, diluted income per share is not applicable to the Company and is not presented.

Income Taxes

The Company uses the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. The measurement of deferred tax assets and liabilities is based on provisions of applicable tax law. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance based on the amount of tax benefits that, based on available evidence, is not expected to be realized.

Research and Development

Research and development costs are expensed as incurred. Total cost for research and development during the six months ended June 30, 2017 and 2016, were \$37,500 and \$0, respectively.

Stock based Compensation

Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services, and applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We will be required to follow a fair value approach using an option-pricing model, such as the Black Scholes option valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. The adoption of this accounting pronouncement has not had a material impact on our results of operations.

Accounts Receivable

An allowance for uncollectible accounts receivable is established by charges to operations for amounts required to maintain an adequate allowance, in management's judgment, to cover anticipated losses from customer accounts and sales returns. Such accounts are charged to the allowance when collection appears doubtful. Any subsequent recoveries are credited to the allowance account.

Inventory

Inventory includes purchased products for resale and raw materials and supplies necessary to manufacture pharmaceuticals, medical devices, and health and beauty products and is stated at the lower of cost (using the first-in, first-out method) or market value. Provisions, when required, are made to reduce excess and expired inventory to its estimated net realizable value. Although competitive pressures and pharmaceutical advancements expose the Company to the risk that estimates of the net realizable value could change in the near term, the Company's agreements with most vendors provide for the right of return of outdated or expired inventory. The Company is exposed to other ownership related risks associated with inventory.

3. RELATED PARTY TRANSACTIONS

The Company borrowed \$109,202 from a shareholder to facilitate the purchase of Dermagen and to cover operating expenses. The balance of \$108,023 is an unsecured loan payable on demand and carries an annual interest rate of 8%, payable every 6 months. The interest accrued as of June 30, 2017 was \$21,605.

4. BANK LINE OF CREDIT

The line of credit was renewed for another year with a maturity date of June 2018. The line of credit was secured by a personal guarantee and accounts receivable. The interest rate on the line of credit is 3.25% and is a variable that changes with the index at a rate of 1.0%, increasing the index to 4.25%. The balance of the line of credit at June 30, 2017 was \$460,000.

AMEXDRUG CORPORATION AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (UNAUDITED)
JUNE 30, 2017

5. BUSINESS SEGMENT INFORMATION

Beginning in 2005, the Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

The following tables describe information regarding the operations and assets of these reportable business segments:

	Distributions	Health and Beauty Products	Total
For the six months ended June 30, 2017			
Sales to external customers	\$ 2,020,497	\$ 3,604,027	\$ 5,624,524
Depreciation and amortization	\$ 1,425	\$ 2,286	\$ 3,711
Segment income (loss) before taxes	\$ 291,045	\$ 352,278	\$ 643,323
Segment assets	\$ 1,124,305	\$ 1,414,019	\$ 2,538,324
For the six months ended June 30, 2016			
Sales to external customers	\$ 2,783,809	\$ 1,714,402	\$ 4,498,211
Depreciation and amortization	\$ 1,508	\$ 2,286	\$ 3,794
Segment income (loss) before taxes	\$ 454,912	\$ 41,377	\$ 496,289
Segment assets	\$ 1,100,169	\$ 832,687	\$ 1,932,856

9. SUBSEQUENT EVENTS

Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has determined there are no subsequent events to be reported.

Item 4. BUSINESS SEGMENT INFORMATION

Beginning in 2005, the Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

Amexdrug Corporation is located at 7251 Condor Street, Commerce, California 90040. Its phone number is (323) 725-3100. Its fax number is (323)725-3133. Its website is www.amexdrug.com. Shares of Amexdrug common stock are traded on the OTC Bulletin Board under the symbol AXRX.OB. The President of Amexdrug has had experience working in the pharmaceutical industry for the past 30 years.

Amexdrug Corporation, through its wholly-owned subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc., is a pharmaceutical and cosmeceutical company specializing in the research and development, manufacturing and distribution of pharmaceutical drugs, cosmetics and distribution of prescription and over-the-counter drugs, private manufacturing and labeling and a quality control laboratory. At Amexdrug Corporation, it is our anticipation to give our clientele the opportunity to purchase cost effective products while attempting to maximize the return of investments to our shareholders.

Amexdrug Corporation distributes its products through its subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc. primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities and other wholesalers and retailers in the state of California.

BioRx Pharmaceuticals, Inc. is a proud member of the National Association of Chain Drug Stores (NACDS). BioRx Pharmaceuticals, Inc. has developed fourteen unique innovative products in the industry under the name Sponix.

Our team of professionals fully pledges the effectiveness of our distinct products.

At this time, we have certain distribution channels with suppliers and customers whom we know and trust, such as Amazon, and hundreds of independent pharmacies.

References in this report to "we," "our," "us," the "company" and "Amexdrug" refer to Amexdrug Corporation and also to our subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care.

BioRx Pharmaceuticals

On November 8, 2004, Amexdrug formed a new subsidiary, BioRx Pharmaceuticals, Inc. as a Nevada corporation. BioRx Pharmaceuticals, Inc. sells pharmacy and laboratory supplies nationwide. BioRx Pharmaceuticals, Inc. is also committed to offer skin care and over the counter (OTC) products that are recommended with trust and faith by physicians, primarily podiatrists and dermatologists. The focus and mission of BioRx Pharmaceuticals, Inc. is to create, develop and manufacture products to help ease pain and restore and maintain the overall well-being of our customers. We strive for high performance and quality. Our commitment is to offer natural and OTC products that are recommended with confidence by doctors and pharmacists and that the customer can use with pleasure. Our compliance program is diligently followed through the Company. BioRx Pharmaceuticals, Inc. maintains high ethics for animal welfare and our products are never tested on animals. All products are made in the USA.

A total of fourteen innovative health and wellness products have been manufactured for sale by BioRx Pharmaceuticals, Inc. These over-the-counter and natural products are effective for treatment of fungus, arthritis, sunburn protection and for healthy feet and nails. BioRx Pharmaceuticals is planning to sell these products to national chain drugstores, sport chain stores, natural food markets and other mass markets. These products are being marketed under the name of Sponix, and are being sold under the name of BioRx Pharmaceuticals.

We have added the BioRx Beauty line to sell to beauty supply stores and professional salons. In addition we are in process of selling electronic consumer products to our customers and on line markets, such as Amazon and Ebay. We believe this new segment will potentially be a great revenue for Amexdrug Corporation's bottom line.

Allied Med, Inc.

On December 31, 2001, Amexdrug acquired all of the issued and outstanding common shares of Allied Med, Inc., an Oregon corporation, in a share exchange in a related party transaction.

Allied Med, Inc., was formed as an Oregon corporation in October 1997 to operate in the pharmaceutical wholesale business of selling a full line of brand name and generic pharmaceutical products, over-the-counter (OTC) drug and non-drug products and health and beauty products to independent and chain pharmacies, alternative care facilities and other wholesalers. At Allied Med our sincere interest is our customers' needs. Our competitive discount pricing allows our customers an advantage.

Allied Med, Inc. (Continued)

Amexdrug assumed the operations of Allied Med, and Amexdrug has been building on the wholesale pharmaceutical operations of Allied Med.

The accompanying financial information includes the operations of Allied Med for all periods presented and the operations of Amexdrug Corporation from April 25, 2000.

Dermagen, Inc.

Amexdrug completed its purchase of Dermagen, Inc. on October 7, 2005. Dermagen, Inc. is now an operating subsidiary of Amexdrug. The acquisition of Dermagen, Inc. is not considered to be an acquisition of a significant amount of assets which would require audited financial statements of Dermagen, Inc.

Dermagen, Inc. is a growing manufacturing company specializing in the manufacturing and distribution of certain pharmaceuticals and health and beauty products. Dermagen, Inc. has a U.S.-FDA registered and state FDA approved manufacturing facility licensed to develop high margin skin and novel health and beauty products for niche markets. Dermagen's competitive advantage is in its excellent product research and development.

Royal Health Care Company

In October 2003, Allied Med, Inc. acquired 100% of the assets of Royal Health Care Company. Royal Health Care Company is a health and beauty company which has sold specially manufactured facial and body creams, arthritic pain relief medications and an exclusive patented hair care product to pharmacies, beauty salons, beauty supply stores and other fine shops. Royal Health Care Company uses the highest quality ingredients for the finest quality products. Each product has been formulated with the essential ingredients and plant extracts to achieve optimum potential and quality. Royal Health Care Company products are manufactured by Dermagen, Inc. in an FDA approved manufacturing facility.

The Royal Health Care Company assets acquired include the "Royal Health Care Company" name, logo, and related trademarks, all formulas to products manufactured for sale under the Royal Health Care Company name, and the Royal Health Care Company list of customers. These intellectual property rights were acquired without cost from a company in which Jack Amin's wife is a principal shareholder. Mr. Amin is the CEO and Chairman of Amexdrug Corporation and Allied Med, Inc. Management believes this acquisition will provide the Company with an opportunity to increase the number of products sold by the Company, and expand the Company's customer base.

On October 28, 2004, Amexdrug formed a new subsidiary, Royal Health Care, Inc. as a Nevada corporation. Royal Health Care, Inc. was formed to manufacture and sell health and beauty products.

Lease Agreements

The Company's principal executive offices and its warehouse and distribution operations moved to 7251 Condor Street, Commerce California in March 2011. The Company leases 27,500 square feet at this location. Approximately 2,500 square feet of the premises is used for executive offices, and the balance of the premises is used for warehouse and distribution operations. The lease was extended to August 31, 2017, with a monthly rent of \$17,500. Payment of the lease has been personally guaranteed by Jack Amin and his wife, Nora Amin. The Company believes this space will be sufficient for at least the next eight months.

The Company's Dermagen, Inc. manufacturing operations are currently located at 2500 East Fender Avenue, Units I & J, Fullerton, California, which is leased under one lease agreement. The lease was extended for a period of one (1) year commencing on March 1, 2016 and ending on February 28, 2017. The lease was extended to February 28, 2018. The Company leases approximately 3,520 square feet at a rental rate of \$2,605 per month. Payment of the lease has been personally guaranteed by Jack Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company believes that the various facilities covered by the leases described above will be sufficient for at least the next twelve months.

Business Segments

Since 2005, Amexdrug has had operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products. Manufacturing includes expertise in research and development for health care industry products, including pharmacy supplies.

Item 5. Identification of directors and executive officers

<u>Name</u>	<u>Title</u>	<u>Number of shares Beneficially Owned</u>		<u>Percent of Class</u>
Jack Amin 7251 Condor Street Commerce, CA 90040	President, Secretary, Treasurer and Director	155,184,040	91.7%	
Rodney S. Baron, MD	Director	0	0.0%	
Behrooz Meimand	Director	0	0.0%	

Item 6. Legal Proceedings

To the best of Amexdrug's knowledge, no governmental authority is contemplating the filing of any material legal proceeding against the Company or its officers and directors.

Legal Counsel

Robert Wilkinson
136 E. South Temple #2400
Salt Lake City, UT 84111
(801) 533-9645

Anthony E. Bell
515 S. Flower Street, 36th Floor
Los Angeles, CA 90071
(213) 973-1288

Auditor

Haynie & Company
50 West Broadway, Suite 600
Salt Lake City, UT 84101
(801) 328-4461

Accountant

G&L Professional Services
2200 Outlet Center Drive, Suite 455
Oxnard, CA 93036
(805) 983-3369

Certifications of Chief Executive Officer and Chief Financial Officer

I, Jack Amin, certify that:

1. I have reviewed this annual report disclosure of Amexdrug Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: August 14, 2017

/s/ Jack Amin
Jack Amin, Chief Financial Officer